Stage four is visible results like weight loss, improved blood sugar, and body composition changes, which typically appear between weeks 4 and 12
These differences may be related to the expression level of GLP-1R on the surface of different tumor cells (75, 98) and may be related to the differences in the results caused by the differences in the cell lines studied, the differences in the study population, and other factors
Although GI AEs are common across all GLP-1 RAs, differences in formulation, dosing, and dual agonism with tirzepatide can influence how well patients tolerate therapy
In fact, higher doses of GLP-1 medications in general are more likely to cause these side effects
Trial participants are followed far more closely than patients in routine care
There are a few things you can do to counteract, including using skincare thats made for and marketed to GLP-1 users